TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase… Read More..

- Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for more than 12 weeks after the viral infection has passed - Enrollment is expected to commence in Q1 2022 TARRYTOWN, N.Y., Jan. 7, 2022 /PRNewswire/… Read More..

PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming virtual investor conferences… Read More..